Table 1.

Clinical and demographic characteristics of the randomized (intent-to-treat) sample

	Full intent-to-treat sample (n=154)		Ketamine+active ASAT sample (n=53)		Ketamine+sham ASAT sample (n=50)		Saline+active ASAT sample (n=51)
Race/ethnicity
Non-Hispanic Caucasian, n (%)	116	(75.32%)	39	(73.58%)	37	(74.00%)	40	(78.43%)
Hispanic/Latino, n (%)	11	(7.14%)	5	(9.43%)	2	(4.00%)	4	(7.84%)
African American, n (%)	7	(4.55%)	3	(5.66%)	2	(4.00%)	2	(3.92%)
Asian, n (%)	9	(5.84%)	4	(7.55%)	2	(4.00%)	3	(5.88%)
More than one race, n (%)	11	(7.14%)	2	(3.77%)	5	(10.00%)	4	(7.84%)
Unknown/incomplete info, n (%)	3	(1.95%)	0	(0.00%)	2	(4.00%)	1	(1.96%)
Sex
Assigned female sex at birth, n (%)	97	(63.0%)	32	(60.4%)	32	(64.0%)	33	(64.7%)
Gender
Cisgender male, n (%)	55	(35.71%)	21	(39.62%)	17	(34.00%)	17	(33.33%)
Cisgender female, n (%)	90	(58.44%)	29	(54.72%)	28	(56.00%)	33	(64.71%)
Transgender: female-to-male, n (%)	1	(0.65%)	1	(1.89%)	0	(0.00%)	0	(0.00%)
Transgender: male-to-female, n (%)	1	(0.65%)	0	(0.00%)	0	(0.00%)	1	(1.96%)
Non-binary or gender fluid, n (%)	2	(1.30%)	1	(1.89%)	1	(2.00%)	0	(0.00%)
Gender undisclosed/unknown, n (%)	5	(3.25%)	1	(1.89%)	4	(8.00%)	0	(0.00%)
Age, mean (SD)	34.26	(10.5)	34.7	(10.1)	34.6	(11.6)	33.5	(9.9)
# of failed adequate ADM trials, mean (SD)	2.64	(1.93)	2.66	(1.59)	2.60	(1.67)	2.67	(2.46)
Taking psychotropic medication, n (%)	122	(79.2%)	40	(75.5%)	42	(84.0%)	40	(78.4%)
Comorbid anxiety disorder, n (%)	94	(61.0%)	30	(56.6%)	30	(60.0%)	34	(66.7%)
MADRS total score (pre-infusion baseline)	32.78	(5.3)	32.28	(5.7)	33.48	(4.9)	32.61	(5.1)

Note: No variables in the table above differed as a function of treatment group according to unpaired t-tests (for continuous variables) or Chi-squared tests (for categorical variables) (p’s>.49). ASAT=Automated Self-Association Training; ADM=antidepressant medication